GNCA vs. VRPX, SCPS, EVLO, CMRA, GNCAQ, ARDS, CALA, STAB, AMPE, and PXMD
Should you be buying Genocea Biosciences stock or one of its competitors? The main competitors of Genocea Biosciences include Virpax Pharmaceuticals (VRPX), Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Aridis Pharmaceuticals (ARDS), Calithera Biosciences (CALA), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), and PaxMedica (PXMD). These companies are all part of the "pharmaceutical products" industry.
Genocea Biosciences vs. Its Competitors
Virpax Pharmaceuticals (NASDAQ:VRPX) and Genocea Biosciences (NASDAQ:GNCA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.
Given Genocea Biosciences' higher possible upside, analysts plainly believe Genocea Biosciences is more favorable than Virpax Pharmaceuticals.
In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.
32.2% of Virpax Pharmaceuticals shares are held by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Genocea Biosciences' return on equity of -182.88% beat Virpax Pharmaceuticals' return on equity.
Virpax Pharmaceuticals has higher earnings, but lower revenue than Genocea Biosciences.
Virpax Pharmaceuticals has a beta of 1.49, suggesting that its stock price is 49% more volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500.
Summary
Genocea Biosciences beats Virpax Pharmaceuticals on 5 of the 9 factors compared between the two stocks.
Get Genocea Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNCA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GNCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Genocea Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:GNCA) was last updated on 8/16/2025 by MarketBeat.com Staff
MarketBeat All Access